Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1852W HIGH $1.45
Volume
123.49 K
Value Traded
84.94 K
Short % Float
12.4%
+11.11%Week
+34.2%1 Month
-35.83%3 Month
-63.1%6 Month
-99.89%5 Year
-99.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
15.78 M
EPS (TTM)
-1.09
P/E Ratio
-
Ent. Value
13.79 M
Total Shares
49.88 M
Float Shares
23.78 M
Insiders
52.32%
Institutions
31.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
AEON Catalyst Timeline
Dated clinical, regulatory and corporate events for AEON Biopharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for AEON Biopharma, Inc.
217Total events
5Upcoming
38Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Type B MeetingABP-450FDA Meeting
FDA Type 2b meeting feedback received for ABP-450 biosimilar development plan
▲Preclinical PoCABP-450Preclinical
Positive pilot forced degradation results supporting analytical comparability of ABP-450 to BOTOX
▲Quarterly UpdateCorporate
Regained compliance with NYSE American continued listing standards
▲Other Regulator MilestoneEx-US Regulatory
Regained full compliance with NYSE American continued listing requirements
▼Equity OfferingCorporate
Sold additional shares pursuant to partial exercise of over-allotment option
▼Equity OfferingCorporate
Closed underwritten public offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
Pricing of upsized $13.75 million public offering with milestone warrants
▲Poster PresentationABP-450Presentation
Poster presentation of structural and functional comparability data for ABP-450 vs BOTOX at AHS 2026
chronic migrainesource ↗
◆Poster PresentationABP-450Presentation
Poster presentation at 2026 AAN Annual Meeting: Establishing Primary Structure Comparability Between ABP-450 and OnabotulinumtoxinA
◆Poster PresentationABP-450Presentation
Poster presentation at 2026 AAN Annual Meeting: Establishing Primary Structure Comparability Between ABP-450 and OnabotulinumtoxinA
◆Type B MeetingABP-450FDA Meeting
Planned BPD Type 2b meeting with FDA to discuss remaining biosimilar development plan
▼Quarterly UpdateCorporate
Received additional NYSE American notice for non-compliance with Section 1003(a)(ii)
▲FDA Feedback ReceivedABP-450FDA Meeting
FDA BPD Type 2a meeting feedback supporting ABP-450 analytical similarity strategy under 351(k) pathway
▲Equity OfferingCorporate
Closing of $6 million PIPE financing and Daewoong note exchange reducing debt by >90%
▲FDA Feedback ReceivedABP-450FDA Meeting
Positive FDA BPD Type 2a meeting with clear framework for analytical plan
biosimilar to BOTOXsource ↗
▲Equity OfferingCorporate
$6 million PIPE financing and Daewoong note exchange reducing debt by >90%
▲Debt Royalty FinancingCorporate
Daewoong note exchange reducing outstanding debt by more than 90%
◆Type B MeetingABP-450FDA Meeting
FDA BPD Type 2a meeting rescheduled to January 21, 2026
biosimilar to BOTOXsource ↗
▲Debt Royalty FinancingCorporate
Execution of exchange agreement with Daewoong to exchange $15M notes plus accrued interest into new equity, $1.5M new notes due 2030, and cash-exercise warrant for 8M shares
◆Type B MeetingABP-450FDA Meeting
FDA Type 2a meeting to review analytical development plan and initial data
◆Timing GuidanceABP-450Presentation
Update on outcome of BPD Type 2a meeting expected after completion and receipt of official FDA minutes
▲FDA Feedback ReceivedABP-450FDA Meeting
Positive analytical data submitted to FDA for ABP-450
biosimilar to BOTOXsource ↗
▼Equity OfferingCorporate
PIPE financing of $6 million with potential additional capital via warrants
▲Biomarker DataABP-450Clinical Data
Positive biosimilarity data: identical amino-acid sequencing and highly similar functional characteristics to BOTOX
▲Preclinical PoCABP-450Preclinical
Positive initial comparative analytical results confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX
◆Debt Royalty FinancingCorporate
Daewoong convertible note exchange: $15M principal plus accrued interest exchanged for equity, new note, and warrants
Past FDA Catalysts and PDUFA Decisions
How AEON actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | ABP-450 (prabotulinumtoxinA) injection | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F17 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 97%
Micro Cap(rank 638 of 658)
Percentile Rank
AEON Biopharma, Inc. has significant pipeline risk (17/100), with $323M risk-adjusted pipeline value, led by ABP-450 in Cervical Dystonia (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABP-450 Small moleculeCompletedNCT04871451 | Cervical Dystonia | Phase 2 | COMPLETED | 112 | Jul 24, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every AEON program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ABP-450 | chronic migraine | 2026-06-04 | 93%-99% sequence coverage across the core neurotoxin (BoNT/A1) and accessory proteins; no variant peptides observed between ABP-450 and BOTOX®; all ABP-450 lots fell within predefined equivalence criteria established from BOTOX® reference resultsRead More | AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache SocietyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| LYNCH TIMOTHY P10% Owner | Buy | 1,150,000 6,500,000 held | $0.21 | 08/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AEON
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 139.00 K | 257.56 K | -0.16% ( -414.00) |
AEON Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AEON ranks across every disease it competes in
Competitive Position is a premium feature
See how AEON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAEON News
AEON▲ +15.8%on this news
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
AEON Biopharma received positive feedback from the FDA during its Type 2b meeting regarding the development of ABP-450 as a biosimilar to BOTOX. The FDA indicated that previously completed studies could support AEON's application, allowing for a potentially streamlined development path. AEON plans to submit an IND for a pharmacodynamic study in late 2026, aiming to integrate various lines of evidence to support its biosimilarity claims.
Read more →AEONAEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
AEON has announced positive results from a pilot study demonstrating that ABP-450 exhibits comparable rates of potency loss to BOTOX® under thermal stress. The study also revealed similar oxidation patterns at methionine sites for both products. These findings provide analytical evidence supporting the comparability of ABP-450 to BOTOX® and lay the groundwork for AEON's upcoming multi-lot studies.
Read more →AEON▼ -5.8%on this news· ran to -19% by day 3
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
AEON Biopharma will participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth Conference in New York City on September 10, 2026. The company aims to advance its biosimilar product ABP-450 for therapeutic use, targeting full-label market entry in the U.S. The therapeutic neurotoxin market is valued at over $3 billion annually, presenting a substantial opportunity for AEON.
Read more →AEONAEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
AEON Biopharma has appointed Dr. Paul Lee as Acting Chief Regulatory Officer, enhancing its regulatory leadership. Dr. Lee, a former Deputy Director at the FDA's Office of Neuroscience, will guide AEON's regulatory strategy for ABP-450, a biosimilar to BOTOX. His expertise is expected to significantly benefit the company's interactions with the FDA as it progresses through the biosimilar development pathway.
Read more →AEON▼ -19%on this newsshared move
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
AEON has reported expanded structural data that supports the molecular similarity of its product ABP-450 to BOTOX®. The new peptide-mapping methods have improved the coverage of the active botulinum neurotoxin primary sequence from 93% to 98%. Additionally, the analysis shows that there is 100% amino acid identity across all regions examined, along with preserved disulfide bond architecture.
Read more →AEONAEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
AEON Biopharma reported its second quarter 2026 financial results, highlighting a successful $15.3 million financing that supports the development of ABP-450, a biosimilar to BOTOX. The company received positive feedback from the FDA regarding its analytical similarity strategy and aims to obtain further guidance for the next development phase. Additionally, AEON restored its compliance with NYSE American listing requirements.
Read more →AEONAEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
AEON Biopharma has announced that it has regained compliance with NYSE American's continued listing standards after addressing previously identified deficiencies. This follows a successful public offering that raised approximately $13.6 million. The company is now positioned to pursue full-label market entry for its biosimilar product ABP-450, which targets the therapeutic neurotoxin market.
Read more →AEON▲ +10.8%on this news
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
AEON Biopharma has announced the pricing of its public offering, aiming to raise approximately $13.75 million, with potential additional proceeds of $29.6 million from milestone warrants. The offering includes shares of common stock and warrants linked to the company's biosimilar product, ABP-450, targeting the therapeutic neurotoxin market. The funds will be used for working capital and supporting biosimilarity testing for ABP-450.
Read more →AEONAEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
AEON Biopharma presented new data at the AHS Annual Scientific Meeting, demonstrating the structural and functional comparability of ABP-450 to BOTOX®. The findings, which include genomic sequence alignment and potency assays, support the biosimilarity of ABP-450, enhancing its potential for U.S. market entry. This data is crucial for AEON's strategy in the therapeutic neurotoxin market.
Read more →AEONAEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
AEON Biopharma reported its first quarter 2026 financial results, highlighting positive feedback from the FDA regarding its ABP-450 biosimilar development. The company significantly reduced its debt by over 90% through financing transactions. Additionally, AEON appointed John Bencich as Chief Financial Officer to strengthen its leadership team and is preparing for further FDA interactions to advance its product towards full-label approval.
Read more →AEONDisrupting a $3.5B neurotoxin market dominated by a single brand for 30 years CORPORATE PRESENTATION / MAY 2026 NYSEAMERICAN: AEON © 2 0 2 6 A E O N B I O P H A R M A This presentation includes forward-looking state
AEON is actively pursuing the development of ABP-450, a biosimilar to BOTOX, aiming to disrupt the $3.5 billion neurotoxin market. With strong analytical data demonstrating high similarity to BOTOX and successful engagement with the FDA, AEON is on track for full-label approval. Recent financing efforts have bolstered the company’s cash flow and strategic initiatives, positioning it favorably against a long-standing market monopoly. The pathway to market includes navigating complex regulatory requirements and demonstrating equivalent efficacy and safety profiles to potential partners and clinicians.
Read more →AEONAEON Biopharma Sets Annual Shareholder Meeting
AEON Biopharma has scheduled its Annual Shareholder Meeting for June 17, 2026, at its office in Irvine, California. The company is progressing with ABP-450, a biosimilar to BOTOX®, aiming for full-label U.S. entry. However, an audit report has revealed a going concern qualification, highlighting liquidity challenges. Despite upcoming shareholder engagement, the company faces uncertainties over financing and adherence to exchange listing standards.
Read more →AEONAEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
AEON Biopharma, Inc. received a notice from NYSE American indicating non-compliance with continued listing standards following its financial results. The company's stockholders' deficit is approximately $55 million, leading to concerns regarding compliance with multiple sections of the NYSE Company Guide. AEON is executing a plan to regain compliance by August 3, 2026, but failure to meet this deadline may result in delisting. The company continues to trade under the symbol 'AEON' despite its current noncompliance status.
Read more →AEONAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma has announced the grant of inducement awards to newly appointed Chief Financial Officer John Bencich. The awards, consisting of restricted and performance-based stock units, are part of the company's 2025 Employment Inducement Incentive Award Plan. This move comes as AEON works towards gaining full-label access to the U.S. therapeutic neurotoxin market with its product ABP-450, a biosimilar to BOTOX. While the therapeutic market represents a significant opportunity, AEON must navigate challenges related to stock exchange compliance and other uncertainties.
Read more →AEONcomplex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau . ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S
AEON Biopharma has received another notice from NYSE American indicating it is not in compliance with continued listing standards. The company reported significant financial losses, resulting in a $55 million stockholders' deficit. Despite having an approved plan to regain compliance by August 2026, failure to meet standards may result in delisting proceedings. The company's operations and obligations to the SEC remain unaffected by this notice.
Read more →AEON▼ -14.7%on this news
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
AEON Biopharma, Inc. announced its financial results for the year ending December 31, 2025, highlighting positive initial results for its biosimilar ABP-450 in relation to BOTOX. The company received encouraging FDA feedback which supports its continued regulatory efforts for the ABP-450 program. AEON has also strengthened its financial position through PIPE financing, significantly reducing its debt. The development pathway remains contingent upon further analytical testing and regulatory engagement.
Read more →AEONAEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
AEON Biopharma received positive feedback from the FDA following a BPD Type 2a meeting regarding its ABP-450 biosimilar program. The FDA supported AEON's analytical similarity strategy under the 351(k) pathway, acknowledging the challenges of characterizing the botulinum neurotoxin complex. AEON plans to request a BPD Type 2b meeting in 2026 to discuss further development steps.
Read more →AEONAEON Biopharma Appoints John Bencich as Chief Financial Officer
AEON Biopharma has appointed John Bencich as its new Chief Financial Officer, aiming to enhance the company's financial strategy as it approaches critical regulatory milestones. Bencich brings over 25 years of experience in corporate strategy and financial leadership from several biotechnology firms. His role will be integral in supporting the company's growth and execution strategies as they advance their lead biosimilar product, ABP-450, geared towards competing in the $3 billion U.S. therapeutic neurotoxin market. AEON is focused on positioning itself for long-term value creation during this pivotal phase of development.
Read more →About AEON Biopharma, Inc.
Headquarters130 VANTIS DRIVE, ALISO VIEJO, CA, 92656
BIOPHARMAWATCH ELITE PLUS
Trade the next AEON catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime